We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.
- Authors
Smith-Jones, Peter M; Solit, David B; Akhurst, Timothy; Afroze, Farzana; Rosen, Neal; Larson, Steven M
- Abstract
The development of therapeutic inhibitors of key signaling pathways has been hampered by the inability to assess the effect of a drug on its target in the patient. 17-allylaminogeldanamycin (17-AAG) is the first Hsp90 inhibitor to be tested in a clinical trial. It causes the degradation of HER2 and other Hsp90 targets, and has antitumor activity in preclinical models. We have developed a method for imaging the inhibition of Hsp90 by 17-AAG. We labeled an F(ab')2 fragment of the anti-HER2 antibody Herceptin with 68Ga, a positron emitter, which allows the sequential positron-emission tomographic imaging of HER2 expression. We have used this method to quantify as a function of time the loss and recovery of HER2 induced by 17-AAG in animal tumors. This approach allows noninvasive imaging of the pharmacodynamics of a targeted drug and will facilitate the rational design of combination therapy based on target inhibition.
- Publication
Nature biotechnology, 2004, Vol 22, Issue 6, p701
- ISSN
1087-0156
- Publication type
Journal Article
- DOI
10.1038/nbt968